Integral Health Increases Stake in Vera Therapeutics by $3.55 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy VERA?
Source: Fool
- Stake Increase: On February 17, 2026, Integral Health Asset Management disclosed the purchase of 100,000 shares of Vera Therapeutics, valued at approximately $3.55 million, indicating strong confidence in the company's future prospects.
- Increased Ownership: Following this transaction, Integral Health's stake in Vera Therapeutics rises to 4.53%, highlighting its significant position within 13F assets under management and enhancing the diversity of its investment portfolio.
- Strong Market Performance: As of last Friday, shares of Vera Therapeutics were priced at $40.93, reflecting a 48% increase over the past year, significantly outperforming the S&P 500's roughly 16% gain, demonstrating market recognition of its potential.
- Critical Clinical Progress: Vera's lead drug, atacicept, has delivered positive Phase 3 data in IgA nephropathy and is awaiting an FDA decision on July 7, with a potential launch shortly thereafter, which could provide significant commercial opportunities for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VERA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VERA
Wall Street analysts forecast VERA stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 39.750
Low
33.00
Averages
74.08
High
100.00
Current: 39.750
Low
33.00
Averages
74.08
High
100.00
About VERA
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vera Therapeutics Appoints New Chief Legal Officer
- Executive Appointment: Vera Therapeutics has appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately, bringing extensive experience in regulatory approvals, commercialization, and intellectual property management, which will support the company as it approaches the launch of its first-in-class dual BAFF/APRIL inhibitor.
- Enhanced Legal Support: With over 25 years of legal experience in the life sciences sector, including her role as General Counsel at Vaxcyte, Wright-Mitchell's expertise is expected to strengthen Vera's legal capabilities through key milestones and the potential commercial launch of atacicept.
- Product Development Outlook: Vera's lead product candidate, atacicept, aims to treat IgA nephropathy as a subcutaneous injection administered weekly, which is anticipated to change the standard of care for patients and further enhance the company's market position in immunological diseases.
- Strategic Collaboration and Innovation: Vera Therapeutics has secured an exclusive licensing agreement with Stanford University for the development of a next-generation fusion protein targeting BAFF and APRIL, known as VT-109, showcasing the company's broad potential in treating B-cell-mediated diseases.
See More
Kynam Capital Management Cuts Viridian Stake by Over $81 Million
- Stake Reduction: Kynam Capital Management sold 2,957,386 shares of Viridian Therapeutics in Q4 2026, with an estimated transaction value of $81.11 million, indicating a cautious outlook on the company's future performance.
- Holding Proportion Change: Following this transaction, Kynam's stake in Viridian decreased to 2.92%, reflecting a reassessment of asset allocation in its 13F report, which may impact investor confidence in the company.
- Market Performance: Viridian's stock price has surged 76% over the past year, currently priced at $26.98, significantly outperforming the S&P 500's roughly 15% gain, indicating strong market demand for its biotech products.
- R&D Expenditure: Despite facing nearly $339 million in R&D costs and an annual net loss of about $343 million, Viridian's cash reserves of approximately $875 million at year-end provide a financial cushion for future clinical trials and product launches.
See More
Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million
- Share Reduction Details: Kynam Capital disclosed in an SEC filing on February 17, 2026, that it sold 1,720,949 shares of Cogent Biosciences in Q4, with an estimated transaction value of $48.38 million, indicating a cautious approach towards the company's future prospects.
- Ownership Proportion Change: Following this sale, Cogent Biosciences now represents 13.99% of Kynam's reported AUM, yet it remains the fund's largest holding, reflecting ongoing confidence in its core investment despite the reduction.
- Market Performance Analysis: Cogent's stock price surged 360% over the past year, significantly outperforming the S&P 500's 15% gain during the same period, highlighting its strong performance and market recognition in the biotech sector.
- Future Outlook: Cogent's lead product, bezuclastinib, received FDA acceptance, with a target decision date set for December 30, 2026, and with $900.8 million in cash reserves, the company is well-positioned to support future R&D and market expansion efforts.
See More
Integral Health Increases Stake in Vera Therapeutics by $3.55 Million
- Stake Increase: On February 17, 2026, Integral Health Asset Management disclosed the purchase of 100,000 shares of Vera Therapeutics, valued at approximately $3.55 million, indicating strong confidence in the company's future prospects.
- Increased Ownership: Following this transaction, Integral Health's stake in Vera Therapeutics rises to 4.53%, highlighting its significant position within 13F assets under management and enhancing the diversity of its investment portfolio.
- Strong Market Performance: As of last Friday, shares of Vera Therapeutics were priced at $40.93, reflecting a 48% increase over the past year, significantly outperforming the S&P 500's roughly 16% gain, demonstrating market recognition of its potential.
- Critical Clinical Progress: Vera's lead drug, atacicept, has delivered positive Phase 3 data in IgA nephropathy and is awaiting an FDA decision on July 7, with a potential launch shortly thereafter, which could provide significant commercial opportunities for the company.
See More
Integral Health Increases Stake in Vera Therapeutics
- Share Acquisition: Integral Health purchased an additional 100,000 shares of Vera Therapeutics in Q4 2025 for an estimated $3.55 million, reflecting confidence in the company's future potential and strategic direction.
- Position Value Increase: By the end of Q4 2025, Integral Health's total holdings in Vera reached 1,800,000 shares valued at $91.15 million, marking a $41.75 million increase, which indicates strong market sentiment towards the biotech firm.
- Clinical Progress: Vera's lead drug, atacicept, has shown positive Phase 3 results in treating IgA nephropathy, with an FDA decision expected on July 7, 2026, potentially paving the way for commercialization and market entry.
- Financial Outlook: Despite widening losses of approximately $299.6 million in 2025, Vera ended the year with about $714.6 million in cash and investments, with total financing efforts projected to reach around $800 million, ensuring sufficient runway for commercialization efforts.
See More
Eversept Partners Increases Stake in Vera Therapeutics
- Share Acquisition: Eversept Partners added 264,468 shares of Vera Therapeutics in Q4 2026, with an estimated transaction value of $9.39 million, indicating strong confidence in the company's growth potential.
- Position Value Increase: By quarter-end, Eversept's holdings in Vera appreciated by $73.99 million, reflecting both new purchases and stock price increases, thereby reinforcing its investment portfolio in the biopharmaceutical sector.
- Clinical Advancements: Vera's lead drug candidate, atacicept, is under development for treating immunoglobulin A nephropathy and has shown positive Phase 3 results, with an FDA priority review decision expected in July 2026, potentially leading to a swift market launch.
- Financial Readiness: Ending 2025 with approximately $714 million in cash and marketable securities, Vera's management believes this capital is sufficient to fund operations through potential drug approval and launch, demonstrating a solid strategy for future growth.
See More
Vera Therapeutics Appoints New Chief Legal Officer
- Executive Appointment: Vera Therapeutics has appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately, bringing extensive experience in regulatory approvals, commercialization, and intellectual property management, which will support the company as it approaches the launch of its first-in-class dual BAFF/APRIL inhibitor.
- Enhanced Legal Support: With over 25 years of legal experience in the life sciences sector, including her role as General Counsel at Vaxcyte, Wright-Mitchell's expertise is expected to strengthen Vera's legal capabilities through key milestones and the potential commercial launch of atacicept.
- Product Development Outlook: Vera's lead product candidate, atacicept, aims to treat IgA nephropathy as a subcutaneous injection administered weekly, which is anticipated to change the standard of care for patients and further enhance the company's market position in immunological diseases.
- Strategic Collaboration and Innovation: Vera Therapeutics has secured an exclusive licensing agreement with Stanford University for the development of a next-generation fusion protein targeting BAFF and APRIL, known as VT-109, showcasing the company's broad potential in treating B-cell-mediated diseases.
See More
Kynam Capital Management Cuts Viridian Stake by Over $81 Million
- Stake Reduction: Kynam Capital Management sold 2,957,386 shares of Viridian Therapeutics in Q4 2026, with an estimated transaction value of $81.11 million, indicating a cautious outlook on the company's future performance.
- Holding Proportion Change: Following this transaction, Kynam's stake in Viridian decreased to 2.92%, reflecting a reassessment of asset allocation in its 13F report, which may impact investor confidence in the company.
- Market Performance: Viridian's stock price has surged 76% over the past year, currently priced at $26.98, significantly outperforming the S&P 500's roughly 15% gain, indicating strong market demand for its biotech products.
- R&D Expenditure: Despite facing nearly $339 million in R&D costs and an annual net loss of about $343 million, Viridian's cash reserves of approximately $875 million at year-end provide a financial cushion for future clinical trials and product launches.
See More
Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million
- Share Reduction Details: Kynam Capital disclosed in an SEC filing on February 17, 2026, that it sold 1,720,949 shares of Cogent Biosciences in Q4, with an estimated transaction value of $48.38 million, indicating a cautious approach towards the company's future prospects.
- Ownership Proportion Change: Following this sale, Cogent Biosciences now represents 13.99% of Kynam's reported AUM, yet it remains the fund's largest holding, reflecting ongoing confidence in its core investment despite the reduction.
- Market Performance Analysis: Cogent's stock price surged 360% over the past year, significantly outperforming the S&P 500's 15% gain during the same period, highlighting its strong performance and market recognition in the biotech sector.
- Future Outlook: Cogent's lead product, bezuclastinib, received FDA acceptance, with a target decision date set for December 30, 2026, and with $900.8 million in cash reserves, the company is well-positioned to support future R&D and market expansion efforts.
See More
Integral Health Increases Stake in Vera Therapeutics by $3.55 Million
- Stake Increase: On February 17, 2026, Integral Health Asset Management disclosed the purchase of 100,000 shares of Vera Therapeutics, valued at approximately $3.55 million, indicating strong confidence in the company's future prospects.
- Increased Ownership: Following this transaction, Integral Health's stake in Vera Therapeutics rises to 4.53%, highlighting its significant position within 13F assets under management and enhancing the diversity of its investment portfolio.
- Strong Market Performance: As of last Friday, shares of Vera Therapeutics were priced at $40.93, reflecting a 48% increase over the past year, significantly outperforming the S&P 500's roughly 16% gain, demonstrating market recognition of its potential.
- Critical Clinical Progress: Vera's lead drug, atacicept, has delivered positive Phase 3 data in IgA nephropathy and is awaiting an FDA decision on July 7, with a potential launch shortly thereafter, which could provide significant commercial opportunities for the company.
See More
Integral Health Increases Stake in Vera Therapeutics
- Share Acquisition: Integral Health purchased an additional 100,000 shares of Vera Therapeutics in Q4 2025 for an estimated $3.55 million, reflecting confidence in the company's future potential and strategic direction.
- Position Value Increase: By the end of Q4 2025, Integral Health's total holdings in Vera reached 1,800,000 shares valued at $91.15 million, marking a $41.75 million increase, which indicates strong market sentiment towards the biotech firm.
- Clinical Progress: Vera's lead drug, atacicept, has shown positive Phase 3 results in treating IgA nephropathy, with an FDA decision expected on July 7, 2026, potentially paving the way for commercialization and market entry.
- Financial Outlook: Despite widening losses of approximately $299.6 million in 2025, Vera ended the year with about $714.6 million in cash and investments, with total financing efforts projected to reach around $800 million, ensuring sufficient runway for commercialization efforts.
See More
Eversept Partners Increases Stake in Vera Therapeutics
- Share Acquisition: Eversept Partners added 264,468 shares of Vera Therapeutics in Q4 2026, with an estimated transaction value of $9.39 million, indicating strong confidence in the company's growth potential.
- Position Value Increase: By quarter-end, Eversept's holdings in Vera appreciated by $73.99 million, reflecting both new purchases and stock price increases, thereby reinforcing its investment portfolio in the biopharmaceutical sector.
- Clinical Advancements: Vera's lead drug candidate, atacicept, is under development for treating immunoglobulin A nephropathy and has shown positive Phase 3 results, with an FDA priority review decision expected in July 2026, potentially leading to a swift market launch.
- Financial Readiness: Ending 2025 with approximately $714 million in cash and marketable securities, Vera's management believes this capital is sufficient to fund operations through potential drug approval and launch, demonstrating a solid strategy for future growth.
See More
